Search Results

CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.

• Authors : Li, Cheng¹ (AUTHOR); Cui, Qiulin¹ (AUTHOR); Wang, Xuanhui¹ (AUTHOR)

• Source: BMC Cancer. 5/20/2024, Vol. 24 Issue 1, p1-8. 8p.

Record details

Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).

• Authors : Goto, Hironobu¹ (AUTHOR); Oshikiri, Taro¹ (AUTHOR) ; Kato, Takashi¹ (AUTHOR)

Subjects: *NIVOLUMAB; *CISPLATIN; *IPILIMUMABJAPAN

• Source: PLoS ONE. 4/18/2024, Vol. 19 Issue 4, p1-8. 8p.

Record details

Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy.

• Authors : Chen, Yonghe^1,2,3 (AUTHOR); Chen, Xiaojiang⁴ (AUTHOR); Lin, Yi¹ (AUTHOR)

• Source: BMC Cancer. 2/23/2024, Vol. 24 Issue 1, p1-9. 9p.

Record details

Clinical effect of neoadjuvant chemotherapy combined with laparoscopic surgery for patients with colorectal cancer.

• Authors : Hong-yan Ma¹; Yu-hui Zhou¹; Lian-zhong Gao²

• Source: Tropical Journal of Pharmaceutical Research. Dec2023, Vol. 22 Issue 12, p2511-2516. 6p.

Record details

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.

• Authors : Shigenori Ei¹; Shinichiro Takahashi¹ ; Toshihito Ogasawara¹

• Source: Gut & Liver. Sep2023, Vol. 17 Issue 5, p698-710. 13p.

Record details

Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study.

• Authors : Han, Sujun¹ (AUTHOR); Ji, Zhigang² (AUTHOR); Jiang, Junhui³ (AUTHOR)

• Source: Cancer Medicine. Jun2023, Vol. 12 Issue 11, p12106-12117. 12p.

Record details

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.

• Authors : Cheng, Daoan¹ (AUTHOR); Zhao, Weiqing¹ (AUTHOR); Chen, Rui¹ (AUTHOR)

• Source: World Journal of Surgical Oncology. 2/3/2023, Vol. 21 Issue 1, p1-8. 8p.

Record details

肺癌化疗原则专家共识.

• Source: Evaluation & Analysis of Drug-Use in Hospitals of China. 2022, Vol. 22 Issue 12, p1428-1438. 11p.

Record details

Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer.

• Authors : Dou, He¹ (AUTHOR); Jia, Siyuan¹ (AUTHOR); Ba, Yuling¹ (AUTHOR)

Subjects: *NEOADJUVANT chemotherapy; *CANCER patients; *EPIDERMAL growth factor receptorsCHINA

• Source: Journal of Cancer Research & Clinical Oncology. Nov2023, Vol. 149 Issue 15, p14185-14204. 20p.

Record details

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials.

• Authors : Wu, Dawei¹ (AUTHOR); Huang, Huiyao¹ (AUTHOR); Zhang, Minghui² (AUTHOR)

• Source: Journal of Hematology & Oncology. 2/8/2022, Vol. 15 Issue 1, p1-4. 4p.

Record details